aibioORGO Organogenesis Holdings Inc.
Organogenesis Holdings (ORGO) news
Top story · Aug 6, 2026 · SEC filing 8-K
Organogenesis signs a material agreement
Latest Organogenesis Holdings news
We have not published a story on Organogenesis Holdings yet. When there is news, it will appear here.
Organogenesis Holdings annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $564.2 million | $482.0 million |
| Research and development | $44.5 million | $50.3 million |
| Net income (loss) | $37.0 million | $861,000 |
| Cash from operations | -$10.3 million | $14.2 million |
| Cash and equivalents | $93.7 million | $135.6 million |
Questions about Organogenesis Holdings
What is the ticker symbol of Organogenesis Holdings?
Organogenesis Holdings Inc. trades under the ticker ORGO on NASDAQ.
Where is Organogenesis Holdings listed?
Organogenesis Holdings Inc. is listed on NASDAQ.
What is the SEC CIK of Organogenesis Holdings?
The SEC Central Index Key (CIK) for Organogenesis Holdings Inc. is 1661181. Its filings are on SEC EDGAR.
How many shares does Organogenesis Holdings have outstanding?
128,674,548 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06.
Which country or territory is Organogenesis Holdings listed under?
Our directory records Organogenesis Holdings Inc. under United States.
What does Organogenesis Holdings do?
Our directory classifies Organogenesis Holdings Inc. as: Biopharma / pharmaceuticals. This is a directory classification, not a description of the pipeline.
What is the ISIN of Organogenesis Holdings?
The ISIN recorded for Organogenesis Holdings Inc. is US68621F1021.
Does aibio.space cover Organogenesis Holdings?
aibio.space lists Organogenesis Holdings Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Organogenesis Holdings incorporated?
SEC records list its state or country of incorporation as DE.
What was Organogenesis Holdings's revenue last year?
$564.2 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Organogenesis Holdings profitable?
Organogenesis Holdings Inc. reported net income of $37.0 million for the fiscal year ended Dec 31, 2025, and used $10.3 million of cash in operations, per its annual report to the SEC.
How much does Organogenesis Holdings spend on research and development?
$44.5 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Organogenesis Holdings have?
$46.1 million in cash at Jun 30, 2026, per its 10-Q.
What is Organogenesis Holdings's market cap?
We do not publish live share prices. In its annual report, Organogenesis Holdings Inc. put the market value of shares held by non-affiliates (public float) at $299.4 million as of Jun 30, 2025.
Is Organogenesis Holdings a smaller reporting company?
SEC records list Organogenesis Holdings Inc.'s filer category as: Accelerated filer.
Investor discussion: Organogenesis Holdings
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
Stock chart
SEC filings and registration
- SEC name
- Organogenesis Holdings Inc.
- CIK
- 1661181
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- ORGO (Nasdaq)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Accelerated filer
- Business address
- 85 DAN ROAD, CANTON, MA, 02021
- Phone
- 781-575-0775
- Shares outstanding
- 128,674,548 as of 2026-07-31 (10-Q filed 2026-08-06)
- Former names
- Avista Healthcare Public Acquisition Corp.
Recent filings
Listing details
- Company
- Organogenesis Holdings Inc.
- Ticker
- ORGO
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Biopharma / pharmaceuticals
- ISIN
- US68621F1021
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction